Kraig Biocraft Laboratories Announces Patent Filing on Artificial Spider Silk Breakthrough
September 30 2010 - 9:30AM
Marketwired
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to
announce that a provisional patent application has been filed by
the University of Notre Dame on the artificial spider silk
technology revealed at the Company's joint press conference
yesterday with the University of Notre Dame. The patent filing
covers all of the breakthrough technology revealed at the press
conference, including artificial spider silk and the methods used
to create transgenic silkworms capable of spinning artificial
spider silk and recombinant fiber.
Pursuant to the provisions of Kraig Biocraft Laboratories
collaborative research and intellectual property agreement with the
University, the Company has an option for a global exclusive
license to use the technology commercially. The Company is happy to
inform its shareholders that it has now exercised that option.
"We built this company with this moment in mind. Our exclusive
commercial license was essentially pre-negotiated at the time we
entered into the collaborative research agreement," explained CEO
Kim Thompson. "The next few months will be a very exciting time for
Kraig as we work toward our vision for commercialization of this
new and exciting technology. We are rapidly moving from being
exclusively research and development to entering a marketable
product and deliverable biotechnology stage."
For more information on the University's view of this spider
silk technology breakthrough you can visit
http://newsinfo.nd.edu/.
For more information on Kraig Biocraft Laboratories please visit
the Company's web site: http://www.KraigLabs.com
Statements in this press release about the company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "hopes," "develops," "researching," "research,"
"potential," "could" or other words or phrases of similar import.
Similarly, statements in this release that describe the Company's
business strategy, outlook, objectives, plans, intentions or goals
should all be considered forward-looking statements. All such
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those in forward-looking statements. Management cautions that
its ability to further its research, and create commercially-viable
products may be affected by the competitive environment, the
Company's financial condition and its ability to raise sufficient
capital to meet the financial obligations of its business plan and
to fund its continuing operations.
CONTACT: Ben Hansel (720) 288-8495 Email Contact
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024